Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02669563 · ClinicalTrials.gov registry record · Early Phase 1
An Exploratory Study of 18F-Labeled Hydroxyphenethylguanidines in Heart Failure Patients
A Early Phase 1 study, sponsored by University of Michigan.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 16
- Enrollment target
NCT02669563: Completed Early Phase 1 study, sponsored by University of Michigan.
NCT02669563 is a Early Phase 1 study that has completed, run by University of Michigan. The registered enrollment target is 16 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (70% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02669563, a Early Phase 1 study, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The main goal of this study is to test two new radioactive drugs, 4-\[18F\]fluoro-meta-hydroxyphenethylguanidine (\[18F\]4F-MHPG) and 3-\[18F\]fluoro-para-hydroxyphenethylguanidine (\[18F\]3F-PHPG) in human subjects with congestive heart failure. Evaluations of these imaging agents will include their uptake in heart, lungs and liver, their metabolic breakdown in blood, and their kinetics in the heart. Based on these studies, the better of the two drugs will be chosen for further studies in patients with heart disease. After the better compound is chosen, additional measures of its imaging properties, metabolism and pharmacokinetics will be done in subjects with heart failure.
Primary Outcome
These data on the relative imaging properties and metabolism of \[18F\]4F-MHPG and \[18F\]3F-PHPG in heart failure patients will be used to select the lead radiotracer for further clinical development.
Interventions
- DRUG [18F]4F-MHPG
- DRUG [18F]3F-PHPG
- DRUG [13N]ammonia
- DRUG [11C]HED
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2015-12 |
| Est. Completion | 2016-12 |
| Phase | Early Phase 1 |
What the finished NCT02669563 record still lists
NCT02669563 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (70% lower).
The record links to 0 conditions, and to 4 interventions - of which [18F]4F-MHPG is the first listed.
NCT02669563 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02669563 about?
NCT02669563 is a clinical study titled "An Exploratory Study of 18F-Labeled Hydroxyphenethylguanidines in Heart Failure Patients". The main goal of this study is to test two new radioactive drugs, 4-\[18F\]fluoro-meta-hydroxyphenethylguanidine (\[18F\]4F-MHPG) and 3-\[18F\]fluoro-para-hydroxyphenethylguanidine (\[18F\]3F-PHPG) in human subjects with congestive heart failure. Evaluations of these imaging agents will include the...
What is the current status of trial NCT02669563?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 16 participants. The study started on 2015-12. Estimated completion is 2016-12.
What interventions are being tested in trial NCT02669563?
The interventions under investigation include: [18F]4F-MHPG (DRUG), [18F]3F-PHPG (DRUG), [13N]ammonia (DRUG), [11C]HED (DRUG).
Who is sponsoring clinical trial NCT02669563?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02669563's enrollment target sits among peer trials
16 1370th of 2000 higher than 598 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia